Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (890)	3/24/2000 5:30:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

When analyzing a biotechnology stock, it is best to take cues from the lawyers who write prospectuses Chuckle. That's about as sensible as taking your cues from the Yahoo pump'n'dump artists. "We don't have any products ... we may never have any products ... even if we (courtesy some divine intervention) eventually had a product the FDA might not approve it ... we could get sued .... we could run out of money ... our patent rights are uncertain ... our key scientists might walk... our competitors are all much bigger and better than us ..." Sound like any biotechs you know? Peter

To: Jim Oravetz who wrote (890)	3/24/2000 11:18:00 PM
From: Miljenko Zuanic	Respond to of 52153

<<Mr. Kranda, the CEO, says by the end of the year the company will have filed patents on 1,500 different proteins and their effects in various diseases, information that will go into its database. Do these have any value? >> Incredible how quickly they are (not only OGS) discovering function of the new proteins??? Average 3-5 new ones per day! Yes, right! In his/her dream. Before it took scientists (I mean serious hard work of the serious people) several years to figure out function(s) of the new proteins in real word on what it means for opportunity as new therapeutic target. Than, as the science evolve, this initial discovery may change one way or another. Example is REGN Angio-1 function. Now they want to figure out function(s) of the ~80-100K new genes/proteins in few months/years. Based on how quickly they are applying for new FUNCTION PATENTS. Miljenko

To: Jim Oravetz who wrote (890)	3/30/2000 7:52:00 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 52153

Biochips: from sci-fi to critical tech by Margaret Quan eet.com Once relegated to science fiction, chips that analyze biological material to diagnose disease, aid in drug discovery and deliver medicine inside the body will provide the basis for major research and commercial breakthroughs in the 21st century. In 2010, a patient may go to a doctor's office for a blood test with a lab-on-a-chip device that tells the doctor in real-time if a patient's illness will respond well to a drug based on his DNA. The chip could also confirm the patient's identity, diagnose disease and even be used to establish paternity. Indeed, these are heady times for electronics engineers and researchers marrying semiconductor technologies and techniques with biology, chemistry and genetics. John Santini Jr., PhD, a former Massachusetts Institute of Technology researcher, heads MicroChips, a Cambridge, Mass., startup developing controlled-release microchips that deliver drugs inside or outside the body. The company is in the early stage of developing technology, but its goal is to develop a silicon chip with tiny wells filled with drug compounds that can be released in the body in a controlled manner via a pre-programmed microchip. Although the field of biochips is lucrative today, the path to the biochip was not always clear. Santini admits the idea of such a device was science fiction years ago-especially a microchip device that could operate on its own in the body. snip.... Not sure where to put this link, but thought this might be appropriate. "New" technology and all with mentions of: Motorola, Nanogen, Affymetrix Inc., and Hyseq Inc. Jim